{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:26:20Z","timestamp":1783646780172,"version":"3.55.0"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T00:00:00Z","timestamp":1503014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Because of the absence of the time course of histological nonalcoholic fatty hepatitis with subsequent fibrotic progression, the effective approaches available for controlling the onset and progression of non-alcoholic steatohepatitis (NASH) remain limited. Therefore, we detected the serum and liver tissue related lipid metabolism disorder, liver pathology and relative molecular makers alteration dynamically in a high fat-sucrose diet during different time points. High fat-sucrose diet significantly increased the serum lipid level on day 10. The excess lipid accumulation in liver was referred to as simple steatosis after the feeding of a high fat-sucrose diet for 20 days. The high fat-sucrose diet induced a hepatic inflammation response on day 30. Similarly, hepatic fibrosis was also initiated on day 30 and gradually formed from the 30th to the 50th day. Oxidative stress may be related with the process from NASH to liver fibrosis. Insulin resistance was involved in the progression from hepatic steatosis to NASH with hepatic fibrosis from the 20th to the 50th day. In conclusion, we established a high fat-sucrose diet induced nonalcoholic fatty hepatitis with liver fibrosis rat model, which presented the time course of histological nonalcoholic steatohepatitis and the initiation and progression change of characteristic molecular makers in the process from steatosis to hepatic fibrosis.<\/jats:p>","DOI":"10.3390\/ijms18081681","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T04:12:17Z","timestamp":1503288737000},"page":"1681","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive Study of Multiple Stages Progressing to Nonalcoholic Steatohepatitis with Subsequent Fibrosis in SD Rats"],"prefix":"10.3390","volume":"18","author":[{"given":"Lulu","family":"Wang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susu","family":"Wu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxuan","family":"Cai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Ma","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengcun","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoru","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Tibetan Medicine Research, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining 810008, China"},{"name":"Qinghai Key Laboratory of Tibetan Medicine Pharmacology and Safety Evaluation, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining 810008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 211198, China"},{"name":"Key Laboratory of Tibetan Medicine Research, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining 810008, China"},{"name":"Qinghai Key Laboratory of Tibetan Medicine Pharmacology and Safety Evaluation, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining 810008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/1751-2980.12291","article-title":"Nonalcoholic fatty liver disease\u2014Current status and future directions","volume":"16","author":"Demir","year":"2015","journal-title":"J. Dig. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20848","DOI":"10.1038\/srep20848","article-title":"Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/ajg.2012.314","article-title":"Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in korean adults","volume":"107","author":"Kwon","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1001\/archinte.164.19.2169","article-title":"Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults","volume":"164","author":"Kim","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1499-3872(13)60021-1","article-title":"Therapeutic approaches to non-alcoholic fatty liver disease: Past achievements and future challenges","volume":"12","author":"Jia","year":"2013","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cld.2012.05.003","article-title":"Management of nonalcoholic steatohepatitis: An evidence-based approach","volume":"16","author":"Mahady","year":"2012","journal-title":"Clin. Liv. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5009\/gnl.2012.6.2.149","article-title":"NASH is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications","volume":"6","author":"Farrell","year":"2012","journal-title":"Gut Liv."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"DeFronzo, R.A., and Ferrannini, E. (2015). Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). International Textbook of Diabetes Mellitus, John Wiley & Sons, Ltd.. [4th ed.].","DOI":"10.1002\/9781118387658"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mazen Noureddin, M.D., Alexanian, D., and Kaplowitz, N. (2015). Non-alcoholic fatty liver disease (NAFLD): The lipid disease of the liver and the effect of statins. Lipid Manag., 149\u2013173.","DOI":"10.1007\/978-3-319-11161-2_9"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.drudis.2015.10.015","article-title":"Emerging therapeutic targets for the treatment of hepatic fibrosis","volume":"21","author":"Fagone","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MOL.0b013e3282ff5e55","article-title":"Hepatic triglyceride synthesis and nonalcoholic fatty liver disease","volume":"19","author":"Choi","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1073\/pnas.1203218109","article-title":"Nuclear receptor PPAR\u03b3-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3945\/ajcn.113.063792","article-title":"Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism","volume":"98","author":"Musso","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40161","DOI":"10.1074\/jbc.M112.417014","article-title":"Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-\u03b1 production","volume":"287","author":"Landes","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2006.tb00292.x","article-title":"Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-\u03b2 as major players and therapeutic targets","volume":"10","author":"Gressner","year":"2006","journal-title":"J. Cell. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.molmed.2006.10.001","article-title":"Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease","volume":"12","author":"Videla","year":"2006","journal-title":"Trends Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Saito, K., Uebanso, T., Maekawa, K., Ishikawa, M., Taguchi, R., Nammo, T., Nishimakimogami, T., Udagawa, H., Fujii, M., and Shibazaki, Y. (2015). Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis. Sci. Rep., 5.","DOI":"10.1038\/srep12466"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/j.1440-1746.2008.05543.x","article-title":"Animal models of NASH: Getting both pathology and metabolic context right","volume":"23","author":"Larter","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of homa modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: From steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/MOG.0b013e328337b0c4","article-title":"Recent advances in nonalcoholic fatty liver disease","volume":"26","author":"Cheung","year":"2010","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2010.04.033","article-title":"Down-regulation of SREBP-1c is associated with the development of burned-out nash","volume":"53","author":"Nagaya","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.3390\/nu7064995","article-title":"Hepatic steatosis as a marker of metabolic dysfunction","volume":"7","author":"Fabbrini","year":"2015","journal-title":"Nutrients"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656566.2014.876992","article-title":"New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease","volume":"15","author":"Sahebkar","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2009.03.008","article-title":"Kupffer cells in non-alcoholic fatty liver disease: The emerging view","volume":"51","author":"Baffy","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cca.2011.04.013","article-title":"The role of oxidative stress in non-alcoholic steatohepatitis","volume":"412","author":"Koek","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_30","first-page":"1077","article-title":"Role of oxidative stress in non-alcoholic steatohepatitis","volume":"64","author":"Mitsuyoshi","year":"2006","journal-title":"Nihon Rinsho."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tang, T., Sui, Y., Lian, M., Li, Z., and Hua, J. (2013). Pro-inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081949"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0168-8278(14)60787-X","article-title":"O147 hepatic stellate cells are the major source of collagen in murine models of liver fibrosis","volume":"60","author":"Lemberger","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2036.2007.03246.x","article-title":"Gi epidemiology: Nonalcoholic fatty liver disease","volume":"25","author":"Angulo","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jhep.2010.07.054","article-title":"Insulin resistance and oxidative stress: Two therapeutic targets in non-alcoholic steatohepatitis","volume":"54","author":"Voican","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3109\/00365521.2010.497938","article-title":"A novel non-alcoholic steatohepatitis animal model featured with insulin resistance, hepatic inflammation and fibrosis","volume":"45","author":"Zhao","year":"2010","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/labinvest.2013.123","article-title":"A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance","volume":"93","author":"Adkins","year":"2013","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S-969","DOI":"10.1016\/S0016-5085(15)33312-6","article-title":"Tu2046 early compensatory mechanism of the liver after the initial accumulation of fat in a diet-induced nafld model","volume":"148","author":"Smith","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.dld.2015.12.036","article-title":"Impact and mechanisms of insulin resistance on liver damage progression in a mouse model of non-alcoholic steatohepatitis (NASH)","volume":"48","author":"Meroni","year":"2016","journal-title":"Dig. Liv. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/8\/1681\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:42:41Z","timestamp":1760208161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/8\/1681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8]]}},"alternative-id":["ijms18081681"],"URL":"https:\/\/doi.org\/10.3390\/ijms18081681","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,18]]}}}